Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 21, Issue 6, 2005, Pages 340-352

  Cristello, Francesca ^a,b   Cela, Vito ^a   Artini, Paolo Giovanni ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Aromatase inhibitors; Clomifene citrate; Diet; Gonadotropin; Metformin; Ovarian drilling; Polycystic ovary syndrome

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CETRORELIX; CLOMIFENE CITRATE; FOLLITROPIN; GANIRELIX; GLITAZONE DERIVATIVE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; INSULIN SENSITIZING AGENT; LETROZOLE; LUTEINIZING HORMONE; METFORMIN; PIOGLITAZONE; RECOMBINANT FOLLITROPIN; ROSIGLITAZONE; TROGLITAZONE;

ABDOMINAL DISCOMFORT; ANDROGEN BLOOD LEVEL; ANOVULATION; ARTICLE; BIRTH DEFECT; BODY MASS; CLINICAL TRIAL; DIARRHEA; FEMALE INFERTILITY; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC SURGERY; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; MENSTRUAL CYCLE; MULTIPLE PREGNANCY; MUSCLE CRAMP; NAUSEA; NEEDLE; NEGATIVE FEEDBACK; NONHUMAN; OBESITY; OVARIAN DRILLING; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; SURGICAL TECHNIQUE;

ANOVULATION; FEMALE; HUMANS; INFERTILITY, FEMALE; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME;

EID: 30344434018     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500463360     Document Type: Article

References (103)

1. Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987;1:235-245.
2. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries - a common finding in normal women. Lancet 1988;1:870-872.
3. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082.
4. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanri ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011.
5. Norman RJ. Hyperandrogenaemia and the ovary. Mol Cell Endocrinol 2002;191:113-119.
6. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989-993.
7. Ibanez L, Potau N, Ferrer A, Rodriguez-Hierro F, Marcos MV, De Zegher F. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002;87:5702-5705.
8. Ibanez L, de Zegher F, Potau N. Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. J Endocrinol Invest 1998;21:558-566.
9. Ibanez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 2004;144:23-29.
10. Battaglia C, Regnani G, Mancini F, Iughetti L, Bernasconi S, Volpe A, Flamigni C, Venturoli S. Isolated premature pubarche: ultrasonographic and color Doppler analysis - a longitudinal study. J Clin Endocrinol Metab 2002;87:3148-3154.
11. Ong KK, Potau N, Petty CJ, Jones R, Ness AR, Honour JW, de Zegher F, Ibanez L, Dunger DB; Avon Longitudinal Study of Parents and Children Study Team. Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J Clin Endocrinol Metab 2004;89:2647-2651.
12. Ibanez L, Potau N, Dunger D, de Zegher F. Precocious pubarche in girls and the development of androgen excess. J Pediatr Endocrinol Metab 2000; 13(Suppl 5):1261-1263.
13. Ibanez L, Valls C, Marcos MV, Ong K, Dunger DB, De Zegher F. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. J Clin Endocrinol Metab 2004;89:4331-4337.
14. Abassi F, Reaver GM. Evaluation of the quantitative insulin sensitivity index as an estimate of insulin sensitivity in humans. Metabolism 2002;51:235-237.
15. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51:581-586.
16. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001;16:1995-1998.
17. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
18. Dunaif A. Molecular mechanisms of insulin resistance in the polycystic ovary syndrome. Semin Reprod Endocrinol 1994;12:15-20.
19. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovary disease. J Clin Endocrinol Metab 1980;50:113-116.
20. Barbieri RL, Hornstein MD. Hyperinsulinemia and ovarian hyperandrogenism: cause and effect. Endocrinol Metab Clin North Am 1988;17:685-703.
21. Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, Furlani L, Caputo M, Muggeo M. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952-960.
22. Legro R, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694-2698.
23. Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, Richmond W, Johnston DG, Franks S. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf) 1996;44:277-284.
24. Birdsall MA, Farquhar CM. Polycystic ovaries in pre- and post-menopausal women. Clin Endocrinol (Oxf) 1996;44:269-276.
25. Meirow D, Raz I, Yossepowitch O, Brzezinski A, Rosler A, Schenker JG, Berry EM. Dyslipidaemia in polycystic ovary syndrome: different groups, different aetiologies? Hum Reprod 1996;11:1848-1853.
26. Wild RA. Obesity, lipids, cardiovascular risk and androgen excess. Am J Med 1995; 98(Suppl):27S-32S.
27. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catherization. Ann Intern Med 1997;126:32-35.
28. Battaglia C, Mancini F, Persico N, Zaccaria V, de Aloysio D. Ultrasound evaluation of PCO, PCOS and OHSS. Reprod Biomed Online 2004;9:614-619.
29. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:505-514.
30. Jarvela IY, Sladkevicius P, Kelly S, Ojha K, Campbell S, Nargund G. Comparison of follicular vascularization in normal versus polycystic ovaries during in vitro fertilization as measured using 3-dimensional power Doppler ultrasonography. Fertil Steril 2004;82:1358-1363.
31. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-191.
32. Kistner RW. Peritubal and periovarian adhesions subsequent to wedge resection of the ovaries. Fertil Steril 1969;20:35-42.
33. Gjoannaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril 1984;4:20-25.
34. Tulandi T. Atlas of laparoscopic and hysteroscopic techniques for gynecologists. London: WB Saunders; 1999. pp 93-95.
35. Daniel JF, Miller W. Polycystic ovaries treated by laparoscopic laser vaporization. Fertil Steril 1989;51:232-236.
36. Felemban A, Tan SL, Tulandi T. Laparoscopic treatment of polycystic ovaries with insulated needle cautery: a reappraisal. Fertil Steril 2000;73:266-269.
37. Li TC, Saravelos H, Chow MS, Chisabingo R, Cooke ID. Factors affecting the outcome of laparoscopic ovarian drilling for polycystic ovarian syndrome in women with anovulatory infertility. Br J Obstet Gynaecol 1998;105:338-344.
38. Heylen SM, Puttemans PJ, Brosens IA. Polycystic ovarian disease treated by laparoscopic argon laser capsule drilling: comparison of vaporization versus perforation technique. Hum Reprod 1994;9:1038-1042.
39. Greenblatt E, Camper RF. Endocrine changes after laparoscopic ovarian cutery in polycystic ovarian syndrome. Am J Obstet Gynecol 1987;42:517-518.
40. Kovacs G, Buckler H, Bangah M, Outch K, Burger H, Healy D, Baker G, Phillips S. Treatment of anovulation due to polycystic ovarian syndrome by laparoscopic ovarian cautery. Br J Obstet Gynaecol 1991;98:30-35.
41. Sumioki H, Utsunomiya T. Ovarian drilling. In: Kempers LR, Cohen J, Haney AF, Yongers JB, editors. Fertility and reproduction medicine, New York: Elsevier Science; 1998. pp 537-539.
42. Saleh AM, Khalil HS. Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2004:83:614-621.
43. El Helw BA, Ghorab MNM, El Attar E. Surgical induction of ovulation in women with polycystic ovary syndrome: a critical analysis of published data. Middle East Fertility Society Journal 1996;1.
44. Mio Y, Toda T, Tanikawa M, Terado H, Harada T, Terakawa N. Transvaginal ultrasound-guided follicular aspiration in the management of anovulatory infertility associated with polycystic ovaries. Fertil Steril 1991;56:1268-1269.
45. De Geyter C, De Geyter M, Castro E, Bals-Pratsch M, Nieschlag E, Schneider HP. Experience with transvaginal ultrasound-guided aspiration of supernumerary follicles for the prevention of multiple pregnancies after ovulation induction and intrauterine insemination. Fertil Steril 1996;65:1163-1168.
46. Ferraretti AP, Gianaroli L, Magli MC, Iammarrone E, Feliciani E, Fortini D. Transvaginal ovarian drilling: a new surgical treatment for improving the clinical outcome of assisted reproductive technologies in patients with polycystic ovary syndrome. Fertil Steril 2001;76:812-816.
47. Kiddy DS, Hamilton-Fairley D, Seppala M, Koistinen R, James VH, Reed MJ, Franks S. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf) 1989;31:757-763.
48. Pasquali R, Antenucci D, Casimirri F, Venturoli S, Paradisi R, Fabbri R, Balestra V, Melchionda N, Barbara L. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989;68:173-179.
49. Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705-2712.
50. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998;13:1502-1505.
51. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002;13:251-257.
52. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-1474.
53. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75:310-315.
54. Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002;77:101-106.
55. Yarali H, Yildiz BO, Demirol A, Zeyneloglu HB, Yigit N, Bukulmez O, Koray Z. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod. 2002;17:289-294.
56. Palomba S, Falbo A, Orio F Jr, Manguso F, Russo T, Tolino A, Annamaria C, Dale B, Zullo F. A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod 2005;20:2879-2886.
57. George SS, George K, Irwin C, Job V, Selvakumar R, Jeyaseelan V, Seshadri MS. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Hum Reprod 2003;18:299-304.
58. Sturrock ND, Lannon B, Fay TN. Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol 2002;535:469-473.
59. O'Dea JPK, Wieland RG, Hallberg MC, Llerena LA, Zorm EM, Genuth SM. Effect of dietary weight loss on sex steroid binding, sex steroids, and gonadotrophins in obese premenopausal women. J Lab Clin Med 1979;93:1004-1008.
60. Malkawi HY, Qublan HS, Hamaideh AH. Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. J Obstet Gynaecol 2003;23:289-293.
61. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004;19:2474-2483.
62. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893-902.
63. Balen AH, Tan SL, MacDougall J, Jacobs HS. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993; 8: 959-964.
64. Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. Br Med J 1998;297:1024-1026.
65. Regan L, Owen EJ, Jacob HS. Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet 1990;336:1141-1144.
66. Sagle M, Bishop K, Ridley N, Alexander FM, Michel M, Bonney RC, Beard RW, Franks S. Recurrent early miscarriage and polycystic ovaries. Br Med J 1988;297:1027-1028.
67. Watson H, Kiddy DS, Hamilton-Fairley D, Scanlon MJ, Barnard C, Collins WP, Bonney RC, Franks S. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage. Hum Reprod 1993;8:829-833.
68. Gray RH, Wu LY. Subfertility and risk of spontaneous abortion. Am J Public Health 2000;90:1452-1454.
69. Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abortion. Br Med J 1989;299:541-545.
70. Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod 1994;9:1328-1332.
71. Craig LB, Ke RW, Kutteh WH. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril 2002;78:487-490.
72. Van der Spuy ZM, Dyer SJ. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:755-771.
73. Homburg R. Clomiphene citrate - end of an era? A mini-review. Hum Reprod 2005;20:2043-51.
74. Jain JK, Kuo J. Pregnancy outcomes with increased clomiphene citrate dose. Gynecol Endocrinol 2004;19:141-145.
75. Kelekci S, Saygili-Yilmaz E, Inan I, Eminsoy G. A trial of a new regimen with clomiphene citrate administration to reduce the antiestrogenic effects on reproductive end organs. Eur J Obstet Gynecol Reprod Biol 2004;116:54-57.
76. Lopez E, Gunby J, Daya S, Parrilla JJ, Abad L, Balasch J. Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy. Reprod Biomed Online 2004;94:382-390.
77. Palomba S, Orio F Jr, Falbo A, Manguso F, Russo T, Cascella T, Tolino A, Carmina E, Colao A, Zullo F. Prospective parallel randomized double-blind double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in non-obese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4068-4074.
78. Homburg R. The management of infertility associated with polycystic ovary syndrome. Reprod Biol Endocrinol 2003;1:109.
79. Van der Meer M, Hompes P, de Boer J, Schats R, Schoemaker J. Cohort size rather than follicle-stimulating hormone threshold levels determines ovarian sensitivity in polycystic ovary syndrome. J Clin Endocrinol Metab 1988;83:423-426.
80. Homburg R, Howles CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, reflections and refinements. Hum Reprod Update 1999;5:493-499.
81. Seibel MM, Kamrava MM, McArdle C, Taymor ML. Treatment of polycystic ovarian disease with chronic low-dose follicle stimulating hormone: biochemical changes and ultrasound correlation. Int J Fertil 1984;29:39-43.
82. Polson DW, Mason HD, Saldahna MBY, Franks S. Ovulation of a single dominant follicle during treatment with low-dose pulsatile FSH in women with PCOS. Clin Endocrinol (Oxf) 1987;26:205-212.
83. Homburg R, Levi T, Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril 1995;63:729-733.
84. Hedon B, Hugues JN, Emparaire JC, Chabaud JJ, Barbereau D, Boujenah A, Howles CM, Truong F. A comparative prospective study of a chronic low-dose versus a conventional ovulation stimulation regimen using recombinant human follicle-stimulating hormone in anovulatory infertile women. Hum Reprod 1998;13:2688-2692.
85. Tummon I, Gavrilova-Jordan L, Allemand MC, Session D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand 2005;84:611-616.
86. Homburg R, Eshel A, Kilborn J, Adams J, Jacobs HS. Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries. Hum Reprod 1990;5:32-37.
87. Olivennes F, Ayoubi JM, Fanchin R, Rongieres-Bertrand C, Hamamah S, Bouchard P, Frydman R. GnRH antagonist in single-dose applications. Hum Reprod Update 2000;6:313-317.
88. Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R. The use of Gn-RH antagonist in ovarian stimulation. Hum Reprod Update 2002;8:279-290.
89. Reissmann T, Schally AV, Bouchard P, Riethmiiller H, Engel J. The LHRH antagonist cetrorelix: a review. Hum Reprod Update 2000;6:322-331.
90. Elkind-Hirsch KE, Webster BW, Brown CP, Vernon MW. Concurrent ganirelix and follitropin β therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome. Fertil Steril 2003;79:603-607.
91. Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani PG. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 2005;20:2421-2425.
92. Guido M, Belosi C, Selvaggi L, Lattanzi F, Apa R, Fulghesu AM, Lanzone A. The effect of age on the ovarian response to gonadotropin and on pregnancy rate in polycystic ovary syndrome. Gynecol Endocrinol 2003;17:215-221.
93. Baird DT, Collins J, Egozcue J, Evers LH, Gianaroli L, Leridon H, Sunde A, Templeton A, Van Steirteghem A, et al.; ESHRE Capri Workshop Group. Fertility and ageing. Hum Reprod Update 2005;11:261-276.
94. Leridon H. Can assisted reproduction technology compensate for the natural decline in fertility with age? A model assessment. Hum Reprod 2004;19:1548-1553.
95. Lipton A, Demers L, Harvey H, Kambic K, Grossberg H, Brady C, Adlercruetz H, Trunet PF, Santen RJ. Letrozole (GCS 20264). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995;75:2132-2138.
96. Iveson T, Smith I, Ahern J, Smithers D, Trunet P, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993;53:266-270.
97. Mitwally MFM, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75:305-309.
98. Al-Omari WR, Sulaiman WR, Al-Hadithi N. Comparison of two aromatase inhibitors in women with clomiphene resistant polycystic ovary syndrome. Int J Gynecol Obstet 2004;85:289-291.
99. Mitwally MFM, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig 2004;11:406-15.
100. Kafali H, Iriadam M, Ozardali I, Demir N. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res 2004;35:103-108.
101. Goswami SK, Das T, Chattopadhyay R, Sawhney V, Chaudhury K, Chakravarty BN, Kabir SN. A randomised single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Hum Reprod 2004;19:2031-2035.
102. Al-Fozan H, Al-Khadouri M, Tan SL, Tulandi T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril 2004;82:1561-1563.
103. Mitwally MFM, Biljan MM, Casper RF. Pregnancy outcome after the use of an oral aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 2005;192:381-386.